slides · global inventory
Sparkline
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 22,963
Current window 14,311-14,340
Pages 766
Rows per page 30
Arc
14,311-14,340 of 22,963
14
The slide uses a mix of pie charts for composition and bar charts for trends.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Financial PerformanceLoop · Cost Of Inaction1 hit
15
HTLF company presentation slide.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Financial PerformanceLoop · Cost Of Inaction1 hit
16
The slide provides a snapshot of portfolio health for a specific loan segment.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Financial PerformanceLoop · Cost Of Inaction1 hit
17
The slide uses a mix of bar charts and pie charts to illustrate portfolio composition and performance.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Financial PerformanceLoop · Cost Of Inaction1 hit
18
Includes a waterfall chart for uninsured deposits and a stacked bar chart for deposit flows.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Financial PerformanceLoop · Cost Of Inaction1 hit
19
The slide uses four donut charts to illustrate the composition of deposits across different dimensions.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Financial PerformanceLoop · Cost Of Inaction1 hit
20
Includes non-GAAP adjustments for AOCI in certain metrics.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Financial PerformanceLoop · Cost Of Inaction1 hit
21
Includes definitions of non-performing loans and assets in the footer.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Future Outlook1 hit
22
The top left chart is a waterfall bridge showing the change in allowance balance from 12/31/2022 to 9/30/2023.Heartland Financial USA | Results Presentation Deck | 35 slides · Heartland Financial USA
Conference presentation Investor relations Beat · Future Outlook1 hit
01
Includes date and ticker symbol.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Hook1 hit
02
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Hook1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Hook1 hit
04
Uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative impacts.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
07
Uses icon-based visualization to represent market expansion from 5% of hospitals to a much broader network.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
08
The slide highlights the structural difference of the NXC-201 molecule compared to Abecma, Carvykti, and CART-ddBCMA.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
09
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
10
The slide uses a comparative timeline visualization to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
11
The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
12
The slide uses a process flow diagram to illustrate the disease mechanism and a human anatomy diagram to show clinical manifestations.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
13
The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
14
The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
16
Includes a footer citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
17
Includes detailed clinical trial references in the footer.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
18
The slide uses a two-column layout to track progress for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
20
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
21
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit